European liver specialists recommend `mix-and-match` approach to new hepatitis C drugs
Cinnamon Girl said
Apr 14, 2014
The European Association for the Study of the Liver has issued new guidelines for the treatment of hepatitis C which recommend that wherever possible, patients should be treated with the newest direct-acting antivirals
EASL is also encouraging European physicians to combine products from different pharmaceutical companies to achieve the most potent interferon-free regimens, often in advance of full phase III trial data, in its new hepatitis C treatment guidelines issued on Friday at the International Liver Congress in London.
The guidelines move beyond US recommendations issued in January, which incorporated a small number of off-label uses not included in the US licenses for sofosbuvir and simeprevir. The new guidelines also include daclatasvir, a NS5A inhibitor that is likely to receive approval in Europe later this year.
The European Association for the Study of the Liver has issued new guidelines for the treatment of hepatitis C which recommend that wherever possible, patients should be treated with the newest direct-acting antivirals
EASL is also encouraging European physicians to combine products from different pharmaceutical companies to achieve the most potent interferon-free regimens, often in advance of full phase III trial data, in its new hepatitis C treatment guidelines issued on Friday at the International Liver Congress in London.
The guidelines move beyond US recommendations issued in January, which incorporated a small number of off-label uses not included in the US licenses for sofosbuvir and simeprevir. The new guidelines also include daclatasvir, a NS5A inhibitor that is likely to receive approval in Europe later this year.
Full details and recommendations...
http://www.aidsmap.com/European-liver-specialists-recommend-mix-and-match-approach-to-new-hepatitis-C-drugs/page/2846012/